Amgen's US$27.8 billion deal for Horizon Therapeutics clears key hurdle

In the Media
1 min read

In The Wall Street Journal, White & Case Antitrust partner Eric Grannon discusses the impact of the Federal Trade Commission ending its legal challenge of drugmaker Amgen's US$27.8 billion deal to buy Horizon Therapeutics, avoiding a trial that was set to have started this month.

Grannon said the resolution doesn't require Amgen to give up anything significant and allows the FTC to bow out of litigation rather than risk a loss in district court, noting "The FTC's theory of harm here had little chance of success."

See the full Wall Street Journal article here.

Press contact
For more information please speak to your local media contact.